Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 10/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.39 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | ACACB | O00763 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22585840 | 1.00 | IRAK4 (0.42) | IRAK4HSD11B1MAPK3MAPK1LRRK2 | |
| SCHEMBL22585839 | 0.88 | CHEK1 (0.43) | IRAK4HSD11B1LRRK2 | |
| SCHEMBL31678648 | 0.88 | MAPK3 (0.48) | IRAK4MAPK3MAPK1 | |
| SCHEMBL31678736 | 0.88 | MAPK3 (0.48) | IRAK4MAPK3MAPK1 | |
| SCHEMBL22553554 | 0.88 | CHEK1 (0.43) | IRAK4HSD11B1LRRK2 | |
| SCHEMBL21765581 | 0.84 | PDE4B (0.51) | IRAK4MAPK1 | |
| SCHEMBL21460305 | 0.83 | MEN1 (0.43) | IRAK4 | |
| SCHEMBL18341448 | 0.81 | IRAK4 (0.45) | IRAK4SCN5A | |
| SCHEMBL30906007 | 0.81 | MAPK1 (0.46) | IRAK4MAPK3MAPK1HDAC3HDAC1 | |
| SCHEMBL27093000 | 0.81 | MAPK1 (0.46) | IRAK4MAPK3MAPK1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-11203594-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2021-12-21 | — | — | US | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | PFIZER INC. (US) | 2020-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11203594-B2 | Anti-proliferative agents for treating PAH | EDNRB, EDNRA, PAH | IRAK4 3445/4885HSD11B1 357/4885MAPK3 524/4885 |
| US-20200331909-A1 | ANTI-PROLIFERATIVE AGENTS FOR TREATING PAH | EDNRB, EDNRA, PAH | IRAK4 3445/4885HSD11B1 357/4885MAPK3 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.